Blurbs

Analysts Offer Insights on Healthcare Companies: Cigna (CI), Arrowhead Pharmaceuticals (ARWR) and CytomX Therapeutics (CTMX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cigna (CIResearch Report), Arrowhead Pharmaceuticals (ARWRResearch Report) and CytomX Therapeutics (CTMXResearch Report) with bullish sentiments.

Cigna (CI)

In a report released today, Matthew Borsch from BMO Capital maintained a Buy rating on Cigna, with a price target of $350.00. The company’s shares closed last Thursday at $280.10, close to its 52-week high of $284.46.

According to TipRanks.com, Borsch is a 4-star analyst with an average return of 5.7% and a 60.7% success rate. Borsch covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Encompass Health, and Universal Health.

Cigna has an analyst consensus of Moderate Buy, with a price target consensus of $303.72, representing an 8.2% upside. In a report released today, Mizuho Securities also maintained a Buy rating on the stock with a $330.00 price target.

See today’s best-performing stocks on TipRanks >>

Arrowhead Pharmaceuticals (ARWR)

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Arrowhead Pharmaceuticals today and set a price target of $82.00. The company’s shares closed last Thursday at $46.13.

According to TipRanks.com, Nakae is a 4-star analyst with an average return of 8.0% and a 41.4% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Better Therapeutics, Inc., and Adverum Biotechnologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arrowhead Pharmaceuticals with a $71.63 average price target.

CytomX Therapeutics (CTMX)

BMO Capital analyst Etzer Darout maintained a Buy rating on CytomX Therapeutics today and set a price target of $3.00. The company’s shares closed last Thursday at $1.63, close to its 52-week low of $1.19.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 35.8% and a 52.5% success rate. Darout covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Y-Mabs Therapeutics, and Fate Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CytomX Therapeutics with a $4.00 average price target, representing a 151.6% upside. In a report issued on August 1, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $8.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos